Reviva to Participate in Upcoming Investor Conferences in May 2025
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for CNS, inflammatory and cardiometabolic diseases, has announced its participation in two upcoming investor conferences in May 2025.
CEO Laxminarayan Bhat will attend the Benchmark Healthcare House Call Virtual Investor Conference for a fireside chat and 1x1 meetings on May 29 at 11:15 a.m. ET, and the Lytham Partners Spring 2025 Investor Conference for a company presentation and 1x1 meetings on the same day at 2:00 p.m. ET. Both events will be held virtually.
Reviva Pharmaceuticals (NASDAQ: RVPH), un'azienda farmaceutica in fase avanzata focalizzata sullo sviluppo di terapie per malattie del sistema nervoso centrale, infiammatorie e cardiometaboliche, ha annunciato la sua partecipazione a due conferenze per investitori previste per maggio 2025.
Il CEO Laxminarayan Bhat parteciperà al Benchmark Healthcare House Call Virtual Investor Conference per un incontro informale e riunioni individuali il 29 maggio alle 11:15 ET, e al Lytham Partners Spring 2025 Investor Conference per una presentazione aziendale e riunioni individuali lo stesso giorno alle 14:00 ET. Entrambi gli eventi si terranno in modalità virtuale.
Reviva Pharmaceuticals (NASDAQ: RVPH), una empresa farmacéutica en etapa avanzada enfocada en desarrollar terapias para enfermedades del sistema nervioso central, inflamatorias y cardiometabólicas, ha anunciado su participación en dos próximas conferencias para inversionistas en mayo de 2025.
El CEO Laxminarayan Bhat asistirá a la Benchmark Healthcare House Call Virtual Investor Conference para una charla informal y reuniones uno a uno el 29 de mayo a las 11:15 a.m. ET, y a la Lytham Partners Spring 2025 Investor Conference para una presentación de la empresa y reuniones uno a uno el mismo día a las 2:00 p.m. ET. Ambos eventos se realizarán de forma virtual.
Reviva Pharmaceuticals (NASDAQ: RVPH)는 중추신경계, 염증성 및 심장대사 질환 치료제 개발에 주력하는 후기 단계 제약회사로, 2025년 5월에 예정된 두 건의 투자자 컨퍼런스에 참여할 것임을 발표했습니다.
CEO 락스미나라얀 바트(Laxminarayan Bhat)는 5월 29일 오전 11시 15분(동부시간)에 Benchmark Healthcare House Call Virtual Investor Conference에서 화상 대화 및 1:1 미팅에 참석하며, 같은 날 오후 2시(동부시간)에는 Lytham Partners Spring 2025 Investor Conference에서 회사 발표와 1:1 미팅을 진행할 예정입니다. 두 행사는 모두 온라인으로 개최됩니다.
Reviva Pharmaceuticals (NASDAQ : RVPH), une entreprise pharmaceutique en phase avancée spécialisée dans le développement de thérapies pour les maladies du système nerveux central, inflammatoires et cardiométaboliques, a annoncé sa participation à deux conférences investisseurs prévues en mai 2025.
Le PDG Laxminarayan Bhat participera à la Benchmark Healthcare House Call Virtual Investor Conference pour une discussion informelle et des rencontres individuelles le 29 mai à 11h15 ET, ainsi qu’à la Lytham Partners Spring 2025 Investor Conference pour une présentation de l’entreprise et des réunions individuelles le même jour à 14h00 ET. Les deux événements se tiendront virtuellement.
Reviva Pharmaceuticals (NASDAQ: RVPH), ein Pharmaunternehmen in der späten Entwicklungsphase, das sich auf die Entwicklung von Therapien für ZNS-, entzündliche und kardiometabolische Erkrankungen spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Mai 2025 angekündigt.
CEO Laxminarayan Bhat wird am Benchmark Healthcare House Call Virtual Investor Conference für ein Gespräch am Kamin und Einzelgespräche am 29. Mai um 11:15 Uhr ET teilnehmen sowie am Lytham Partners Spring 2025 Investor Conference für eine Unternehmenspräsentation und Einzelgespräche am selben Tag um 14:00 Uhr ET. Beide Veranstaltungen finden virtuell statt.
- None.
- None.
CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following upcoming investor conferences.
Benchmark Healthcare House Call Virtual Investor Conference
Format: Fireside chat and 1x1 investor meetings
Date: Thursday, May 29, 2025
Time: 11:15 a.m. ET
Location: Virtual
Lytham Partners Spring 2025 Investor Conference
Format: Company presentation and 1x1 investor meetings
Date: Thursday, May 29, 2025
Time: 2:00 p.m. ET
Location: Virtual
Webcast Link: Click Here
To arrange a meeting with management please register for the event Here
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
What investor conferences will RVPH attend in May 2025?
Who will represent Reviva Pharmaceuticals at the May 2025 investor conferences?
What is Reviva Pharmaceuticals' (RVPH) main business focus?
What types of sessions will RVPH participate in during these conferences?
